Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are leading causes of vision loss globally and are commonly treated with intravitreal injections (injections directly into the eye) of anti-vascular endothelial growth factor (VEGF) agents [1,2]. This evidence concerns the gene VEGFA and wet macular degeneration.